Creative Medical Technology Holdings Inc (CELZ)

[hann-d]

You might add

"On October 18, 2017, Creative Medical Technology Holdings announced the completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company’s patented CaverStem™ procedure. Based on the data collected on the trial and there having been no adverse side effects, the procedure has been determined to be safe based on the trial data and the determination from the independent safety monitor. In addition, a similar trial conducted in Europe experienced no adverse or significantly adverse events resulting from the procedure."

I think there may be a time in the future that a continuation of this study could be done for efficacy but this would be more expansive in it's scope and much more expensive. Proven efficacy I think would be the key to insurance approval.